BDNF and Alzheimer disease: Although additional investigation is required, the present findings provide preclinical evidence that oral apigenin may ameliorate AD-associated learning and memory impairment through relieving Aβ burden, suppressing amyloidogenic process, inhibiting oxidative stress, and restoring ERK/CREB/BDNF pathway of cerebral cortex in APP/PS1 mice.